First-in-human Phase Ib Study of ATRC-101, an Engineered Version of a Patient-Derived Antibody Targeting a Tumor-Restricted Ribonucleoprotein Complex.
JOURNAL OF CLINICAL ONCOLOGY(2020)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined